Dr Toni Hazell discusses some difficult scenarios when prescribing contraception, starting with the woman who has obesity ...

Dr Shae Datta, a board-certified neurologist and specialist in brain injuries and vestibular migraine at NYU Langone, said ...

Clinical and radiographic evidence of OA in dogs aged 1 year or older was confirmed in at least one major joint of either a thoracic (shoulder ... an initial dose of 0.2 mg/kg by subcutaneous ...

The likely rationale for this phenomenon is the lack of local anesthetics in the described MDZ-BCD mixture, serving to “auto-numb” the injection site (whether ... and musculocutaneous nerves after ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

This article explores types of immunotherapy for upper GI cancer, how subcutaneous immunotherapy injections work, and considerations for when a doctor may add these types of therapies to a cancer ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

will cancel out the injection’s convenience edge. Before Merck, Roche’s Tecentriq and Bristol Myers Squibb’s Opdivo both have subcutaneous formulations approved by the FDA.

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab).

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European ...

In data the company is presenting at the European Lung Cancer Congress, it said the median injection time per subcutaneous dose was two minutes, down from around 30 minutes for a Keytruda infusion.